{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T09:18:59Z","timestamp":1773479939491,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.saa.2023.123644","type":"journal-article","created":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T11:50:16Z","timestamp":1699703416000},"page":"123644","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Fluorimetric study on a novel FDA-approved combination used for the treatment of overactive bladder syndrome in different matrices"],"prefix":"10.1016","volume":"307","author":[{"given":"Israa M.","family":"Nour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed R.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A.","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Badrawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.saa.2023.123644_b0005","doi-asserted-by":"crossref","first-page":"119258","DOI":"10.1016\/j.saa.2020.119258","article-title":"Flourimetric study on antidiabetic combined drugs; empagliflozin and linagliptin in their pharmaceutical formulation and human plasma, Spectrochim","volume":"248","author":"Elmasry","year":"2021","journal-title":"Acta Part A Mol. Biomol. Spectrosc."},{"key":"10.1016\/j.saa.2023.123644_b0010","doi-asserted-by":"crossref","first-page":"122715","DOI":"10.1016\/j.saa.2023.122715","article-title":"Eco-friendly-assessed micellar-fluorimetric platform for concurrent analysis of empagliflozin and prucalopride succinate in biological fluids: Docking simulation, Spectrochim","volume":"296","author":"Nour","year":"2023","journal-title":"Acta Part A Mol. Biomol. Spectrosc."},{"key":"10.1016\/j.saa.2023.123644_b0015","doi-asserted-by":"crossref","first-page":"122442","DOI":"10.1016\/j.saa.2023.122442","article-title":"Micellar-enhanced and green-assessed first-derivative synchronous spectrofluorimetric approach for concurrent determination of alfuzosin hydrochloride and solifenacin succinate in different matrices: Docking simulation","volume":"293","author":"Sayed","year":"2023","journal-title":"Spectrochim. Acta Part A Mol. Biomol. Spectrosc."},{"key":"10.1016\/j.saa.2023.123644_b0020","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1007\/s10895-022-02942-1","article-title":"Utility of silver-nanoparticles for nano-fluorimetric determination of vancomycin hydrochloride in pharmaceutical formulation and biological fluids: Greenness assessment","volume":"32","author":"Mohamed","year":"2022","journal-title":"J. Fluoresc."},{"key":"10.1016\/j.saa.2023.123644_b0025","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00192-012-1682-6","article-title":"Pathophysiology of overactive bladder","volume":"23","author":"Banakhar","year":"2012","journal-title":"Int. Urogynecol. J."},{"key":"10.1016\/j.saa.2023.123644_b0030","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2014.02.012","article-title":"Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony)","volume":"67","author":"Abrams","year":"2015","journal-title":"Eur. Urol."},{"key":"10.1016\/j.saa.2023.123644_b0035","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ogc.2015.10.002","article-title":"Overactive bladder","volume":"43","author":"White","year":"2016","journal-title":"Obstet. Gynecol. Clin."},{"key":"10.1016\/j.saa.2023.123644_b0040","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.eururo.2018.05.005","article-title":"Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: A randomised, multicentre phase 3 study (SYNERGY II)","volume":"74","author":"Gratzke","year":"2018","journal-title":"Eur. Urol."},{"key":"10.1016\/j.saa.2023.123644_b0045","series-title":"Adrenergic agonists and antagonists, Goodman and Gilman\u2019s The Pharmacological Basis of Therapeutics","first-page":"237","author":"Westfall","year":"2006"},{"key":"10.1016\/j.saa.2023.123644_b0050","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.clinthera.2015.02.021","article-title":"Pharmacokinetics of mirabegron, a \u03b23-adrenoceptor agonist for treatment of overactive bladder, in healthy East Asian subjects","volume":"37","author":"Iitsuka","year":"2015","journal-title":"Clin. Ther."},{"key":"10.1016\/j.saa.2023.123644_b0055","doi-asserted-by":"crossref","first-page":"223","DOI":"10.47191\/ijpbms\/v2-i8-01","article-title":"Development and validation of UV and RP-HPLC methods for simultaneous estimation of mirabegron and solifenacin succinate in their pharmaceutical dosage form","volume":"2","author":"Patel","year":"2022","journal-title":"Int. J. Pharm. Bio Med. Sci."},{"key":"10.1016\/j.saa.2023.123644_b0060","doi-asserted-by":"crossref","first-page":"100976","DOI":"10.1016\/j.scp.2023.100976","article-title":"Earth-friendly-assessed UV-spectrophotometric approaches for concurrent determination of mirabegron and solifenacin succinate in different matrices","volume":"32","author":"Sayed","year":"2023","journal-title":"Sustain. Chem. Pharm."},{"key":"10.1016\/j.saa.2023.123644_b0065","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1556\/1006.2019.32.4.7","article-title":"High-Performance Thin-Layer chromatographic method for the estimation of mirabegron and solifenacin succinate used in the treatment of overactive bladder syndrome","volume":"32","author":"Shah","year":"2019","journal-title":"JPC\u2013Journal Planar Chromatogr TLC."},{"key":"10.1016\/j.saa.2023.123644_b0070","unstructured":"United States Pharmacopeia and National Formulary, (USP 43-NF 38), 2020. United States Pharmacopeial Convention."},{"key":"10.1016\/j.saa.2023.123644_b0075","unstructured":"Ich Q2A (R1). Validation of Analytical Procedures: Text and Methodology 2005 IFPMA Geneva, Switzerland."}],"container-title":["Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S138614252301329X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S138614252301329X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T02:35:28Z","timestamp":1761359728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S138614252301329X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":15,"alternative-id":["S138614252301329X"],"URL":"https:\/\/doi.org\/10.1016\/j.saa.2023.123644","relation":{},"ISSN":["1386-1425"],"issn-type":[{"value":"1386-1425","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fluorimetric study on a novel FDA-approved combination used for the treatment of overactive bladder syndrome in different matrices","name":"articletitle","label":"Article Title"},{"value":"Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.saa.2023.123644","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"123644"}}